Skip to main content

Effects of two different regional citrate anticoagulation CVVH protocols on acid-base status and phosphate supplementation


Regional citrate anticoagulation (RCA) is increasingly used in high bleeding risk patients undergoing CRRT. Regardless of anticoagulation protocol, hypophosphatemia occurs frequently in CRRT. The aim was to evaluate the effects on electrolyte and acid-base status of a new RCA-CVVH protocol using an 18 mmol/l citrate solution combined with a phosphate-containing replacement fluid, compared with a previously adopted RCA-CVVH protocol combining a 12 mmol/l citrate solution with a conventional replacement fluid.


Until September 2011, RCA-CVVH was routinely performed in our centre with a 12 mmol/l citrate solution and a postdilution replacement fluid with bicarbonate (HCO3 - 32, Ca2+ 1.75, Mg2+ 0.5, K+ 2 mmol/l) (protocol A). In cases of metabolic acidosis, not related to inappropriate citrate metabolism and persisting after optimization of RCA-CVVH parameter setting, bicarbonate infusion was scheduled. Starting from September 2011, in order to optimize buffer balance and to reduce the need for phosphate supplementation, a new RCA-CVVH protocol has been designed using an 18 mmol/l citrate solution combined with a recently introduced phosphate-containing replacement fluid with bicarbonate (HCO3 - 30, phosphate 1.2, Ca2+ 1.25, Mg2+ 0.6, K+ 4 mmol/l) (protocol B).


In 30 cardiac surgery patients with AKI, acid-base status and electrolytes have been evaluated comparing protocol A (20 patients, running time 5,283 hours) versus protocol B (10 patients, 1,170 hours) (median (IQR)): pH 7.40 (7.36 to 7.44) versus 7.43 (7.41 to 7.47) (P 0.0001), bicarbonate 22.1 (20.9 to 23.5) versus 24.4 (23.2 to 25.6) mmol/l (P 0.0001), base excess -3.1 (-4.6 to -1.15) versus 0 (-1.5 to 1.1) (P 0.0001), systemic Ca2+ 1.16 (1.1 to 1.23) versus 1.14 (1.08 to 1.19) mmol/l (P 0.0001), phosphate 0.7 (0.5 to 1) versus 1.1 (0.9 to 1.4) mmol/l (P 0.0001). Protocol A required bicarbonate infusion in 90% of patients (6 ± 6.4 mmol/hour) and sodium phosphate supplementation in all cases (4.1 ±3 2.4 g/day). A lower amount of phosphate supplementation (0.9 ± 23 g/day) was needed in 30% of patients undergoing protocol B while bicarbonate infusion was never required. Filter life was comparable (51.8 ± 36.5 vs. 46.8 ± 30.3 hours, P = NS).


Protocol B provided a buffer balance more positive than protocol A and allowed one to adequately control acid-base status without additional bicarbonate infusion and in the absence of alkalosis, despite the use of a standard bicarbonate concentration replacement solution. Furthermore, the combination of a phosphate-containing replacement fluid appeared effective to prevent hypophosphatemia.

Author information



Corresponding author

Correspondence to S Morabito.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Morabito, S., Pistolesi, V., Pistolesi, V. et al. Effects of two different regional citrate anticoagulation CVVH protocols on acid-base status and phosphate supplementation. Crit Care 17, P437 (2013).

Download citation


  • HCO3
  • Hypophosphatemia
  • Replacement Fluid
  • Citrate Solution
  • Regional Citrate Anticoagulation